SEC Info - Astrazeneca PLC - ‘20-F’ for 12/31/06

SEC Info℠

Home

Help

Please Sign In

Astrazeneca PLC – ‘20-F’ for 12/31/06 – ‘EX-12.2’

On: Tuesday, 3/27/07, at 2:10pm ET · For: 12/31/06 · Accession #: 950103-7-768 · File #: 1-11960

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/27/07  Astrazeneca PLC                   20-F       12/31/06   11:5.4M                                   Davis Polk & … LLP 01/FA

Annual Report by a Foreign Private Issuer — Form 20-F
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report by a Foreign Private Issuer           HTML    132K 
 2: EX-4.6      Instrument Defining the Rights of Security Holders  HTML     41K 
 4: EX-8.1      Opinion re: Tax Matters                             HTML     22K 
 7: EX-13.1     Annual or Quarterly Report to Security Holders      HTML      9K 
 3: EX-7.1      Letter re: Non-Reliance upon a Previously Issued    HTML     14K 
                          Audit Report or Completed Interim Review               
 5: EX-12.1     Statement re: Computation of Ratios                 HTML     13K 
 6: EX-12.2     Statement re: Computation of Ratios                 HTML     14K 
 8: EX-15.1     Letter re: Unaudited Interim Financial Information  HTML   3.16M 
 9: EX-15.2     Letter re: Unaudited Interim Financial Information  HTML     11K 
10: EX-15.3     Letter re: Unaudited Interim Financial Information  HTML      9K 
11: EX-15.4     Letter re: Unaudited Interim Financial Information  HTML    487K

EX-12.2 — Statement re: Computation of Ratios

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

EXHIBIT 12.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT 2002

I, Jonathan Richard Symonds, certify that:

1. I have reviewed this annual report on Form 20-F of AstraZeneca PLC;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

4. The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accepted accounting principles;

(c)	Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)	Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

5. The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

March 27, 2007

/s/ J.R. Symonds

J.R. Symonds,

Chief Financial Officer, AstraZeneca PLC

4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/22/22  AstraZeneca PLC                   20-F       12/31/21  192:136M                                   Toppan Merrill/FA
 2/16/21  AstraZeneca PLC                   20-F       12/31/20  191:103M                                   Toppan Merrill/FA
 9/25/07  SEC                               UPLOAD¶     9/25/17    1:21K  AstraZeneca PLC
 8/31/07  SEC                               UPLOAD¶     9/25/17    1:44K  AstraZeneca PLC

↑Top